DCR3检测在肝细胞癌患者中的临床意义
|
摘要
目的:探讨DCR3对HCC的诊断价值和临床意义。
方法:采用ELISA(enzyme linked immunosorbent assay)检测45例正常人血清中的DCR3(decoy receptor 3)水平;再对45例经手术后病理学证实的HCC(hepatocellularcarcinoma)患者分别用ELISA检测其血清中的DCR3水平,用IHC(immunohistochemistry)检测HCC癌组织中及癌旁组织中DCR3蛋白的表达;用RT-PCR(Reverse Transcription Polymerase Chain Reaction)检测其肿瘤组织中及癌旁组织中DCR3基因mRNA的表达。由SPSS13.0统计软件分析。计数资料比较用χ2检验,各组间的计量资料比较采用方差分析,方差不齐时作秩和检验。计算Pearson相关系数判断DCR3与其它变量的相关关系。影响DCR3的多因素分析采用多元线性逐步回归分析。
结果:HCC组血清DCR3水平明显高于正常对照组(P<0.01),且与伴有肝硬化有关(P<0.05);DCR3蛋白在HCC癌组织中表达与血清水平呈正相关(r=0.395,P<0.01),但DCR3血清阳性率高于癌组织IHC(P<0.05),且DCR3蛋白在HCC癌旁组织中不表达;DCR3基因mRNA的表达与DCR3蛋白的表达基本相一致,相应癌旁组织中均为阴性。但其阳性率71.1%(32/45)介于血清学水平75.6%(34/45)和组织学水平60%(26/45)之间。
结论:DcR3升高在HCC的发生发展及浸润转移中起重要作用,通过监测高危人群以及肝癌患者尤其是血清中DcR3水平可能对HCC的筛查、诊断和判断预后有一定意义。
Objective: To investigate the diagnostic value andclinical significance of elevateddecoy receptor 3(DcR3)in patients with hepatocellularcarcinoma(HCC).
Methods: Serum DcR3 levels were measured using enzyme-linked immunosorbent assay(ELISA) in 45 patients with HCC and in the healthy individuals.The expression of DcR3 in HCC tissue was evaluated by immunohistochemistry(IHC).Reverse Transcription Polymerase Chain Reaction(RT-PCR) is used to evaluateThe expression of mRNA about DcR3
Results: The levels of serum DcR3 in HCC patients were higher than that in healthy individuals (P<0.01).The level of serum DcR3 in HCC patients was correlated with the development of cirrhosis(P<0.05).There was a positive correlation betweenthe levels of DcR3 in the serum and HCC tissue(r=0.395,P<0.01). The positive rate of DcR3 inthe serum was significantly higher than that in HCC tissue(P<0.05). DcR3 is negative in the neighboring tissue around The sensitivities of single. The expression of mRNA about DCR3 and DCR3 protein expression basically consistent, is negative in the corresponding neighborly tissue around HCC. But its positive 71.1 percent (32/45) is between serological level 75.6% (34/45) and histological level 60 percent (26 / between 45).
Conclusions: Elevated DcR3 may play an important role in the pathogenesis,development,invasion and metastasis of HCC.It may be of great significance for the screening,diagnosis and prognosis of HCC to simultaneously monitor the levels of DcR3 expecially in the serum level of high-risk populations and HCC patients.
方法:采用ELISA(enzyme linked immunosorbent assay)检测45例正常人血清中的DCR3(decoy receptor 3)水平;再对45例经手术后病理学证实的HCC(hepatocellularcarcinoma)患者分别用ELISA检测其血清中的DCR3水平,用IHC(immunohistochemistry)检测HCC癌组织中及癌旁组织中DCR3蛋白的表达;用RT-PCR(Reverse Transcription Polymerase Chain Reaction)检测其肿瘤组织中及癌旁组织中DCR3基因mRNA的表达。由SPSS13.0统计软件分析。计数资料比较用χ2检验,各组间的计量资料比较采用方差分析,方差不齐时作秩和检验。计算Pearson相关系数判断DCR3与其它变量的相关关系。影响DCR3的多因素分析采用多元线性逐步回归分析。
结果:HCC组血清DCR3水平明显高于正常对照组(P<0.01),且与伴有肝硬化有关(P<0.05);DCR3蛋白在HCC癌组织中表达与血清水平呈正相关(r=0.395,P<0.01),但DCR3血清阳性率高于癌组织IHC(P<0.05),且DCR3蛋白在HCC癌旁组织中不表达;DCR3基因mRNA的表达与DCR3蛋白的表达基本相一致,相应癌旁组织中均为阴性。但其阳性率71.1%(32/45)介于血清学水平75.6%(34/45)和组织学水平60%(26/45)之间。
结论:DcR3升高在HCC的发生发展及浸润转移中起重要作用,通过监测高危人群以及肝癌患者尤其是血清中DcR3水平可能对HCC的筛查、诊断和判断预后有一定意义。
Objective: To investigate the diagnostic value andclinical significance of elevateddecoy receptor 3(DcR3)in patients with hepatocellularcarcinoma(HCC).
Methods: Serum DcR3 levels were measured using enzyme-linked immunosorbent assay(ELISA) in 45 patients with HCC and in the healthy individuals.The expression of DcR3 in HCC tissue was evaluated by immunohistochemistry(IHC).Reverse Transcription Polymerase Chain Reaction(RT-PCR) is used to evaluateThe expression of mRNA about DcR3
Results: The levels of serum DcR3 in HCC patients were higher than that in healthy individuals (P<0.01).The level of serum DcR3 in HCC patients was correlated with the development of cirrhosis(P<0.05).There was a positive correlation betweenthe levels of DcR3 in the serum and HCC tissue(r=0.395,P<0.01). The positive rate of DcR3 inthe serum was significantly higher than that in HCC tissue(P<0.05). DcR3 is negative in the neighboring tissue around The sensitivities of single. The expression of mRNA about DCR3 and DCR3 protein expression basically consistent, is negative in the corresponding neighborly tissue around HCC. But its positive 71.1 percent (32/45) is between serological level 75.6% (34/45) and histological level 60 percent (26 / between 45).
Conclusions: Elevated DcR3 may play an important role in the pathogenesis,development,invasion and metastasis of HCC.It may be of great significance for the screening,diagnosis and prognosis of HCC to simultaneously monitor the levels of DcR3 expecially in the serum level of high-risk populations and HCC patients.
引文
[1]袁青领,黄修燕,郑起.肝细胞分子靶向治疗的研究新进展,医学综述,2010,16(6):849-852.
[2] Ito Y, Sasak Y, Horimoto M, et al . Activation of mitogen activated protein kinase、extracelluar signal2regulated kinase in human hepatocellularcarcinoma. Hepatology , 1998 , 27 : 9572958.
[3] Takahama Y,YamadaY,EmotoK,et al,The prognostic significance of overexpression of the gdecoy receptor for Fas ligand(DCR3) in patients with gastriccareinomus,Cancer, 2002,5(2):61-68
[4] Shen HW,Wu YL,Peng SY.Overexpression and genomic amplification of decoy receptor 3 in hepatocellular carcinoma and significance thereof.Zhonghua Yi Xue Za Zhi,2003,106(1):17-25.
[5] Tsuji S,Hosotani R,Yonehara S,et al,Endogenous decoy receptor3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma Int J Cancer,2003,106(1):17-25.
[6] Pitti RM, Marsters SA , Lawrence DA , et al1 Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer [J ]1 Nature ,1998 ,396 :699-703.
[7] Bai C , Connolly B , Metzker ML , et al1 Overexpression of M68/ DcR3in human gastrointestinal tract tumors independent of gene amplification and its location in a four2gene cluster [J ]1 Proc Natl Acad Sci USA 2000,97(3) :1230-1235.
[8] Gill RM, Hunt JS. Soluble receptor (DcR3) and cellular inhibitor of apoptosis-2 (cIAP-2) protect human cytotrophoblast cells against LIGHTmediated apoptosis. Am J Pathol 2004; 165: 309-317
[9] Yu KY, Kwon B , Ni J , et al1 A newly identified member of tumornecrosis factor receptor superfamily (TR6) suppresses LIGHT2 mediated apoptosis[J ]1 J Biol Chem ,1999 ,274 :13733-13736.
[10] Wan X,ShiG,Semenuk M,et al.DRC3/TR6 modulates immune cell interactions,J Cell Biochem,2003,89(3);603-612.
[11] Shi G,Wu Y,Zhang J,et al. Death decoy receptor TR6/DCR3 inhibits T cell chemotaxis in vitro and in vivo J Immunol,2003,171(7):3407-3414.
[12] HusTL,ChangSJ,etal,modulation of dendritic differen tiation and maturation by decoy receptor 3,J Immumol, 2002,168(10): 4846-4853.
[13] Yang CR,Hsich SL,teng CM,et al,Soluble decoy receptor 3 induces angrogenesis by neultralization of TLIA,a cytokin belonging to tummor necrosis factor superfamily and exhibiting angiostatic aetion,Cancer Res, 2004, 64 (3): 1122-1129.
[14]杨海松竹,陈罡等,肝细胞癌患者血清DCR3水平与临床意义,世界华人消化杂志,2009,17(20):2042-2047.
[15] Li W, Zhang C, Chen C, Zhuang G. Correlation between expression of DcR3 on tumor cells and sensitivity to FasL. Cell Mol Immunol 2007; 4: 455-460
[16] Ashkenazi A.Targeting death and decoy receptors of the tumour-necrosis factor superfamily.Nat Rev Cancer 2002;2:420-430
[17] You RI,Chang YC,Chen PM,Wang WS,Hsu TL,Yang CY,Lee CT,Hsieh SL.Apoptosis of dendritic cells induced by decoy receptor 3(DcR3).Blood 2008;111:1480-1488
[18] Chang YC,Chen TC,Lee CT,Yang CY,Wang HW,Wang CC,HsiehSL.Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3.Blood 2008;111: 5054-5063
[19] Yang CR,Hsieh SL,Ho FM,Lin WW.Decoy receptor 3 increases monocyte adhesion to endothelial cells via NF-kappa B-dependent up- regulation of intercellular adhesion molecule-1,VCAM-1,and IL-8 expression.J Immunol 2005;174:1647-1656
[20] Wan X,Shi G,Semenuk M,Zhang J,Wu J.DcR3/TR6 modulates immune cell interactions.J CellBiochem 2003;89:603-612
[21] Mueller AM,Pedre X,Killian S,David M,Steinbrecher A.The Decoy Receptor 3(DcR3,TNFRSF6B)suppresses Th17 immune responses and is abundant in human cerebrospinal fluid.J Neuroimmunol 2009;209:57-64
[22] Chen C,Zhang C,Zhuang G,Luo H,Su J,Yin P,Wang J.Decoy receptor 3 overexpression and immunologic tolerance in hepatocellular carcinoma (HCC)development.Cancer Invest 2008;26:965-974
[23] Arakawa Y,Tachibana O,Hasegawa M,Miyamori T,Yamashita J,Hayashi Y.Frequentgene amplification and overexpression of decoy receptor 3 in glioblastoma.Acta Neuropathol 2005;109: 294-298
[24] Chen L,Tian X,Li W,Agarwal A,Zhuang G. Expressions of Fas/DcR3 and RGD-FasL mediatedapoptosis in pituitary adenomas.Neurol India 2009; 57:28-30
[25] Macher-Goeppinger S,Aulmann S,Wagener N,Funke B,Tagscherer KE,Haferkamp A, Hohenfellner M,Kim S,Autschbach F,Schirmacher P,Roth W.Decoy receptor 3 is a prognostic factor in renal cell cancer.Neoplasia 2008;10:1049-1056
[26] Li H,Zhang L,Lou H,Ding I,Kim S,Wang L, Huang J,Di Sant'AgnesePA,Lei JY.Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus.Am J Clin Pathol 2005;124:282-287
[27] Tsuji S,Hosotani R,Yonehara S,Masui T,Tulachan SS,Nakajima S,Kobayashi H,Koizumi M,Toyoda E, Ito D,Kami K,Mori T,Fujimoto K,Doi R,Imamura M.Endogenous decoy receptor 3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma.Int J Cancer 2003;106:17-25
[28] Chen PH,Yang CR.Decoy receptor 3 expression in AsPC-1 human pancreatic adenocarcinoma cells via the phosphatidylinositol 3-kinase-,Akt-,and NF-kappa B-dependent pathway.J Immunol 2008;181:8441-8449
[29] Takahama Y,Yamada Y,Emoto K,Fujimoto H, Takayama T,Ueno M,Uchida H,Hirao S,MizunoT,Nakajima Y.The prognostic significance of overexpression of the decoy receptor for Fas ligand(DcR3)in patients with gastric carcinomas.Gastric Cancer 2002;5:61-68
[30]陈罡,党裔武,罗殿中.应用组织微阵列技术检测胃癌组织肿瘤坏死因子受体6的表达及意义.世界华人消化杂志,2008;16:1997-2001.
[31] Chen G,Luo D.Over-expression of decoy receptor3 in gastric precancerous lesions and carcinoma.Ups J Med Sci 2008;113:297-304
[32] Shen HW,Wu YL,Peng SY.[Overexpression and genomic amplification of decoy receptor 3 in hepatocellular carcinoma and significance thereof] Zhonghua Yixue Zazhi 2003;83:744-747
[33] Shen HW,Gao SL,Wu YL,Peng SY.Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fasligand-mediated apoptosis.World J Gastroenterol 2005;11:5926-5930
[34] Mild G,Bachmann F,Boulay JL,Glatz K,Laffer U,Lowy A,Metzger U,Reuter J,Terracciano L,Herrmann R,Rochlitz C.DCR3 locus is a predictive marker for 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer.Int J Cancer 2002;102:254-257
[35] Simon I,Liu Y,Krall KL,Urban N,Wolfert RL,Kim NW,McIntosh MW.Evaluation of the novel serum markers B7-H4,Spondin 2,and DcR3 for diagnosis and early detection of ovarian cancer.Gynecol Oncol 2007;106:112-118
[36] Lee CS,Hu CY,Tsai HF,Wu CS,Hsieh SL,Liu LC,Hsu PN.Elevated serum decoy receptor 3 with enhanced T cell activation in systemic lupus erythematosus.Clin Exp Immunol 2008;151:383-390
[37] HanB, BojalilR, Amezcua-GuerraLM, Springall R, Valderrama-Carvajal H, Wu J,Luo H.DcR3 as a diagnostic parameter and risk factor for systemic lupus erythematosus.Int Immunol 2008;20:1067-1075
[38] Bamias G,Siakavellas SI,Stamatelopoulos KS, Chryssochoou E,Papamichael C,Sfikakis PP.Circulating levels of TNF-like cytokine 1A(TL1A) and its decoy receptor 3(DcR3)in rheumatoid arthritis.Clin Immunol 2008;129:249-255
[1]袁青领,黄修燕,郑起.肝细胞分子靶向治疗的研究新进展.医学综述, 2010, 16(6): 849-852.
[2]Ito Y, Sasak Y, Horimoto M, et al . Activation of mitogen activated protein kinase / extracelluar signal2regulated kinase in human hepatocellularcarcinoma. Hepatology , 1998, 27: 957-958.
[3]Takahama Y, YamadaY, EmotoK, et al, The prognostic significance of over- expression of the gdecoy receptor for Fas ligand(DCR3) in patients with gastric careinomus. Cancer, 2002, 5(2): 61-68.
[4]Shen HW, Wu YL, Peng SY. Overexpression and genomic amplification of decoy receptor 3 in hepatocellular carcinoma and significance thereof.Zhonghua Yi Xue Za Zhi, 2003, 106(1): 17-25.
[5]Tsuji S, Hosotani R, Yonehara S, et al. Endogenous decoy receptor3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma. Int J Cancer, 2003, 106(1): 17-25.
[6]Pitti RM, Marsters SA , Lawrence DA, et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature, 1998, 396:699-703.
[7]Bai C, Connolly B, Metzker ML, et al. Overexpression of M68/ DcR3in human gastrointestinal tract tumors independent of gene amplification and its location in a four2gene cluster. Proc Natl Acad Sci, 2000,97(3) :1230-1235.
[8]Gill RM, Hunt JS. Soluble receptor (DcR3) and cellular inhibitor of apoptosis-2 (cIAP-2) protect human cytotrophoblast cells against LIGHTmediated apoptosis. Am J Pathol, 2004, 165: 309-317.
[9]Yu KY, Kwon B, Ni J, et al. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT2mediated apoptosis. J Biol Chem, 1999, 274: 13733-13736.
[10]Wan X, ShiG, Semenuk M, et al. DRC3/TR6 modulates immune cell interactions. J Cell Biochem, 2003, 89(3): 603-612.
[11]Shi G, Wu Y, Zhang J, et al. Death decoy receptor TR6/DCR3 inhibits T cell chemotaxis in vitro and in vivo. J Immunol, 2003, 171(7): 3407-3414.
[12]HusTL, ChangSJ, et al. Modulation of dendritic differen tiation and maturation by decoy receptor 3. J Immumol, 2002,168(10): 4846-4853.
[13]Yang CR, Hsich SL, Teng CM, et al. Soluble decoy receptor 3 induces angrogenesis by neultralization of TLIA,a cytokin belonging to tummor necrosis factor superfamily and exhibiting angiostatic aetion. Cancer Res, 2004, 64(3): 1122-1129.
[14]杨海松竹,陈罡,党裔武,等.肝细胞癌患者血清DCR3水平与临床意义.世界华人消化杂志, 2009, 17(20): 2042-2047.
[1]吴孟超.原发性肝癌的诊断及治疗进展[J].中国医学科学院报,2008,30(40):363-365.
[2]胡宗泽,张清泉,王兴国,等.38例小肝癌诊断及治疗体会[J].中华普通外科杂志,1997,12(6):329.
[3]Ueno S,Kubo F,Sakoda M,et a1.Efficacy of alatomic resection vs nonanatomic resection for small nodular hepatocellular carcinoma based on gross classification [J].Hepatobiliary Pancreat Surg,2008,15(5):493.500
[4]Regimbeau JM,Kianmanesh R, Farges().Extent of liver resection influences the outcome in Patients with cirrhosis and small hepatocelluIar carcinoma[J].Surgery, 2008,131(3):311—317.
[5]ChenJY,Chaugy ,LuiWY,etal.Clinicopathologic features and factors related to survival of patients with small hepatocellular carcinoma after hepaticresection[J].WorldJSurg,2006,27(3) :294-298.
[6]Mazzaferro V, Regalia E,Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis[ J ]. N Engl J Med,2005, 334 (11) : 693-699.
[7]Yao FY,Ferrell L,Bass NM.d a1.Liver transplantation for hepatocellular carcinoma:expansion of the tum or size does not adversely impact survival[J].Hepatology,2006.33(12);1394-1403.
[8]Poon RTP,Fan ST,Lo CM et a1.Intrahepatic recurrence after curative resection of hepatocellular carcinoma. Longterm results of treatment and prognostic factors[J].AnnSurg ,1999,229(7):216—222.
[9]陈自谦,杨利,杨熙章,等.肝癌介人治疗现状与进展[J].介入放射学杂志,2008,17(3):223—227.
[10]ManabuM, KazushiN, Sugimori K, et al. Successful initial ablation therapy contributes to survival in patients with hepatocellular carcinoma[J]. Would Gastroenterol, 2007, 13 (7) : 1003-1009.
[11]Shiina S, Teratani T,Obi S, et al. A randomized controlled trial of radiofrequency ablation with, ethanol injection for small hepatocellular carcinoma[J]. Gastrocnterology, 2007, 129 (1) : 122-130.
[12]Lin SM,Lin CJ,Lin CC, et al. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less[J]. Gut, 2007, 54 ( 8) :1151-1156.
[13]Mulier S,Mulier P,Ni Y, et al. Comp lications of radiofrequency coagulation of liver turmours [J]. Br J Surg, 2006, 89 (10) :1206-1222.
[14]陈敏山,郑云,张亚奇,等.经皮射射频消融与手术切除治疗小肝癌的疗效比较[J].中华医学杂志,2005,85(2):80-83.
[15]Lu MD Chen JW,XieXY,et.al Hepatocellularcarcinoma , US-guided percutaneous microwave coagulation therapy[J]. Radiology,2006,221(8):167—172.
[16]Richly H, Kup sch P, Passage K, et al. Results of a phase I trial of BAY 43-29006 in combination with doxorubicin in patients with primary hepatic cancer [J]. Int J Clin Pharmacol Ther, 2007, 42(11) : 650-651.
[17]Philip PA,MahoneyMR,Allmer C, et al. PhaseⅡstudy of Erlotinib(OSI-774) in patients with advanced hepatocellular cancer [J]. J Clin Oncol, 2006, 23 (27) : 6657-6663.
[18]张智坚,吴孟超,陈汉,等.术后肝动脉化疗栓塞对提高肝细胞癌术后无瘤生存率的意义[J].中华外科杂志,2002,4O(5):329-331.
[19]Yamakado K,Nakatsuka A.Akeboshi M ,et a1.Combination therapy with radio- frequency ablation and transcatheter chemoembolization for the treatment of hepatocellular carcinoma:Short term recurrences and surviva1.Clin Oncol,2007,11(9):105-109
[20]Lo CM,Hu CL,Chan SC,et a1.A randomized,controled trial ofpostoperative adjuvant interferon therapy after resection of hepatocellular carcinoma[J].Ann Surg,2007,245(6):831—842.
[2] Ito Y, Sasak Y, Horimoto M, et al . Activation of mitogen activated protein kinase、extracelluar signal2regulated kinase in human hepatocellularcarcinoma. Hepatology , 1998 , 27 : 9572958.
[3] Takahama Y,YamadaY,EmotoK,et al,The prognostic significance of overexpression of the gdecoy receptor for Fas ligand(DCR3) in patients with gastriccareinomus,Cancer, 2002,5(2):61-68
[4] Shen HW,Wu YL,Peng SY.Overexpression and genomic amplification of decoy receptor 3 in hepatocellular carcinoma and significance thereof.Zhonghua Yi Xue Za Zhi,2003,106(1):17-25.
[5] Tsuji S,Hosotani R,Yonehara S,et al,Endogenous decoy receptor3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma Int J Cancer,2003,106(1):17-25.
[6] Pitti RM, Marsters SA , Lawrence DA , et al1 Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer [J ]1 Nature ,1998 ,396 :699-703.
[7] Bai C , Connolly B , Metzker ML , et al1 Overexpression of M68/ DcR3in human gastrointestinal tract tumors independent of gene amplification and its location in a four2gene cluster [J ]1 Proc Natl Acad Sci USA 2000,97(3) :1230-1235.
[8] Gill RM, Hunt JS. Soluble receptor (DcR3) and cellular inhibitor of apoptosis-2 (cIAP-2) protect human cytotrophoblast cells against LIGHTmediated apoptosis. Am J Pathol 2004; 165: 309-317
[9] Yu KY, Kwon B , Ni J , et al1 A newly identified member of tumornecrosis factor receptor superfamily (TR6) suppresses LIGHT2 mediated apoptosis[J ]1 J Biol Chem ,1999 ,274 :13733-13736.
[10] Wan X,ShiG,Semenuk M,et al.DRC3/TR6 modulates immune cell interactions,J Cell Biochem,2003,89(3);603-612.
[11] Shi G,Wu Y,Zhang J,et al. Death decoy receptor TR6/DCR3 inhibits T cell chemotaxis in vitro and in vivo J Immunol,2003,171(7):3407-3414.
[12] HusTL,ChangSJ,etal,modulation of dendritic differen tiation and maturation by decoy receptor 3,J Immumol, 2002,168(10): 4846-4853.
[13] Yang CR,Hsich SL,teng CM,et al,Soluble decoy receptor 3 induces angrogenesis by neultralization of TLIA,a cytokin belonging to tummor necrosis factor superfamily and exhibiting angiostatic aetion,Cancer Res, 2004, 64 (3): 1122-1129.
[14]杨海松竹,陈罡等,肝细胞癌患者血清DCR3水平与临床意义,世界华人消化杂志,2009,17(20):2042-2047.
[15] Li W, Zhang C, Chen C, Zhuang G. Correlation between expression of DcR3 on tumor cells and sensitivity to FasL. Cell Mol Immunol 2007; 4: 455-460
[16] Ashkenazi A.Targeting death and decoy receptors of the tumour-necrosis factor superfamily.Nat Rev Cancer 2002;2:420-430
[17] You RI,Chang YC,Chen PM,Wang WS,Hsu TL,Yang CY,Lee CT,Hsieh SL.Apoptosis of dendritic cells induced by decoy receptor 3(DcR3).Blood 2008;111:1480-1488
[18] Chang YC,Chen TC,Lee CT,Yang CY,Wang HW,Wang CC,HsiehSL.Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3.Blood 2008;111: 5054-5063
[19] Yang CR,Hsieh SL,Ho FM,Lin WW.Decoy receptor 3 increases monocyte adhesion to endothelial cells via NF-kappa B-dependent up- regulation of intercellular adhesion molecule-1,VCAM-1,and IL-8 expression.J Immunol 2005;174:1647-1656
[20] Wan X,Shi G,Semenuk M,Zhang J,Wu J.DcR3/TR6 modulates immune cell interactions.J CellBiochem 2003;89:603-612
[21] Mueller AM,Pedre X,Killian S,David M,Steinbrecher A.The Decoy Receptor 3(DcR3,TNFRSF6B)suppresses Th17 immune responses and is abundant in human cerebrospinal fluid.J Neuroimmunol 2009;209:57-64
[22] Chen C,Zhang C,Zhuang G,Luo H,Su J,Yin P,Wang J.Decoy receptor 3 overexpression and immunologic tolerance in hepatocellular carcinoma (HCC)development.Cancer Invest 2008;26:965-974
[23] Arakawa Y,Tachibana O,Hasegawa M,Miyamori T,Yamashita J,Hayashi Y.Frequentgene amplification and overexpression of decoy receptor 3 in glioblastoma.Acta Neuropathol 2005;109: 294-298
[24] Chen L,Tian X,Li W,Agarwal A,Zhuang G. Expressions of Fas/DcR3 and RGD-FasL mediatedapoptosis in pituitary adenomas.Neurol India 2009; 57:28-30
[25] Macher-Goeppinger S,Aulmann S,Wagener N,Funke B,Tagscherer KE,Haferkamp A, Hohenfellner M,Kim S,Autschbach F,Schirmacher P,Roth W.Decoy receptor 3 is a prognostic factor in renal cell cancer.Neoplasia 2008;10:1049-1056
[26] Li H,Zhang L,Lou H,Ding I,Kim S,Wang L, Huang J,Di Sant'AgnesePA,Lei JY.Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus.Am J Clin Pathol 2005;124:282-287
[27] Tsuji S,Hosotani R,Yonehara S,Masui T,Tulachan SS,Nakajima S,Kobayashi H,Koizumi M,Toyoda E, Ito D,Kami K,Mori T,Fujimoto K,Doi R,Imamura M.Endogenous decoy receptor 3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma.Int J Cancer 2003;106:17-25
[28] Chen PH,Yang CR.Decoy receptor 3 expression in AsPC-1 human pancreatic adenocarcinoma cells via the phosphatidylinositol 3-kinase-,Akt-,and NF-kappa B-dependent pathway.J Immunol 2008;181:8441-8449
[29] Takahama Y,Yamada Y,Emoto K,Fujimoto H, Takayama T,Ueno M,Uchida H,Hirao S,MizunoT,Nakajima Y.The prognostic significance of overexpression of the decoy receptor for Fas ligand(DcR3)in patients with gastric carcinomas.Gastric Cancer 2002;5:61-68
[30]陈罡,党裔武,罗殿中.应用组织微阵列技术检测胃癌组织肿瘤坏死因子受体6的表达及意义.世界华人消化杂志,2008;16:1997-2001.
[31] Chen G,Luo D.Over-expression of decoy receptor3 in gastric precancerous lesions and carcinoma.Ups J Med Sci 2008;113:297-304
[32] Shen HW,Wu YL,Peng SY.[Overexpression and genomic amplification of decoy receptor 3 in hepatocellular carcinoma and significance thereof] Zhonghua Yixue Zazhi 2003;83:744-747
[33] Shen HW,Gao SL,Wu YL,Peng SY.Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fasligand-mediated apoptosis.World J Gastroenterol 2005;11:5926-5930
[34] Mild G,Bachmann F,Boulay JL,Glatz K,Laffer U,Lowy A,Metzger U,Reuter J,Terracciano L,Herrmann R,Rochlitz C.DCR3 locus is a predictive marker for 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer.Int J Cancer 2002;102:254-257
[35] Simon I,Liu Y,Krall KL,Urban N,Wolfert RL,Kim NW,McIntosh MW.Evaluation of the novel serum markers B7-H4,Spondin 2,and DcR3 for diagnosis and early detection of ovarian cancer.Gynecol Oncol 2007;106:112-118
[36] Lee CS,Hu CY,Tsai HF,Wu CS,Hsieh SL,Liu LC,Hsu PN.Elevated serum decoy receptor 3 with enhanced T cell activation in systemic lupus erythematosus.Clin Exp Immunol 2008;151:383-390
[37] HanB, BojalilR, Amezcua-GuerraLM, Springall R, Valderrama-Carvajal H, Wu J,Luo H.DcR3 as a diagnostic parameter and risk factor for systemic lupus erythematosus.Int Immunol 2008;20:1067-1075
[38] Bamias G,Siakavellas SI,Stamatelopoulos KS, Chryssochoou E,Papamichael C,Sfikakis PP.Circulating levels of TNF-like cytokine 1A(TL1A) and its decoy receptor 3(DcR3)in rheumatoid arthritis.Clin Immunol 2008;129:249-255
[1]袁青领,黄修燕,郑起.肝细胞分子靶向治疗的研究新进展.医学综述, 2010, 16(6): 849-852.
[2]Ito Y, Sasak Y, Horimoto M, et al . Activation of mitogen activated protein kinase / extracelluar signal2regulated kinase in human hepatocellularcarcinoma. Hepatology , 1998, 27: 957-958.
[3]Takahama Y, YamadaY, EmotoK, et al, The prognostic significance of over- expression of the gdecoy receptor for Fas ligand(DCR3) in patients with gastric careinomus. Cancer, 2002, 5(2): 61-68.
[4]Shen HW, Wu YL, Peng SY. Overexpression and genomic amplification of decoy receptor 3 in hepatocellular carcinoma and significance thereof.Zhonghua Yi Xue Za Zhi, 2003, 106(1): 17-25.
[5]Tsuji S, Hosotani R, Yonehara S, et al. Endogenous decoy receptor3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma. Int J Cancer, 2003, 106(1): 17-25.
[6]Pitti RM, Marsters SA , Lawrence DA, et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature, 1998, 396:699-703.
[7]Bai C, Connolly B, Metzker ML, et al. Overexpression of M68/ DcR3in human gastrointestinal tract tumors independent of gene amplification and its location in a four2gene cluster. Proc Natl Acad Sci, 2000,97(3) :1230-1235.
[8]Gill RM, Hunt JS. Soluble receptor (DcR3) and cellular inhibitor of apoptosis-2 (cIAP-2) protect human cytotrophoblast cells against LIGHTmediated apoptosis. Am J Pathol, 2004, 165: 309-317.
[9]Yu KY, Kwon B, Ni J, et al. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT2mediated apoptosis. J Biol Chem, 1999, 274: 13733-13736.
[10]Wan X, ShiG, Semenuk M, et al. DRC3/TR6 modulates immune cell interactions. J Cell Biochem, 2003, 89(3): 603-612.
[11]Shi G, Wu Y, Zhang J, et al. Death decoy receptor TR6/DCR3 inhibits T cell chemotaxis in vitro and in vivo. J Immunol, 2003, 171(7): 3407-3414.
[12]HusTL, ChangSJ, et al. Modulation of dendritic differen tiation and maturation by decoy receptor 3. J Immumol, 2002,168(10): 4846-4853.
[13]Yang CR, Hsich SL, Teng CM, et al. Soluble decoy receptor 3 induces angrogenesis by neultralization of TLIA,a cytokin belonging to tummor necrosis factor superfamily and exhibiting angiostatic aetion. Cancer Res, 2004, 64(3): 1122-1129.
[14]杨海松竹,陈罡,党裔武,等.肝细胞癌患者血清DCR3水平与临床意义.世界华人消化杂志, 2009, 17(20): 2042-2047.
[1]吴孟超.原发性肝癌的诊断及治疗进展[J].中国医学科学院报,2008,30(40):363-365.
[2]胡宗泽,张清泉,王兴国,等.38例小肝癌诊断及治疗体会[J].中华普通外科杂志,1997,12(6):329.
[3]Ueno S,Kubo F,Sakoda M,et a1.Efficacy of alatomic resection vs nonanatomic resection for small nodular hepatocellular carcinoma based on gross classification [J].Hepatobiliary Pancreat Surg,2008,15(5):493.500
[4]Regimbeau JM,Kianmanesh R, Farges().Extent of liver resection influences the outcome in Patients with cirrhosis and small hepatocelluIar carcinoma[J].Surgery, 2008,131(3):311—317.
[5]ChenJY,Chaugy ,LuiWY,etal.Clinicopathologic features and factors related to survival of patients with small hepatocellular carcinoma after hepaticresection[J].WorldJSurg,2006,27(3) :294-298.
[6]Mazzaferro V, Regalia E,Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis[ J ]. N Engl J Med,2005, 334 (11) : 693-699.
[7]Yao FY,Ferrell L,Bass NM.d a1.Liver transplantation for hepatocellular carcinoma:expansion of the tum or size does not adversely impact survival[J].Hepatology,2006.33(12);1394-1403.
[8]Poon RTP,Fan ST,Lo CM et a1.Intrahepatic recurrence after curative resection of hepatocellular carcinoma. Longterm results of treatment and prognostic factors[J].AnnSurg ,1999,229(7):216—222.
[9]陈自谦,杨利,杨熙章,等.肝癌介人治疗现状与进展[J].介入放射学杂志,2008,17(3):223—227.
[10]ManabuM, KazushiN, Sugimori K, et al. Successful initial ablation therapy contributes to survival in patients with hepatocellular carcinoma[J]. Would Gastroenterol, 2007, 13 (7) : 1003-1009.
[11]Shiina S, Teratani T,Obi S, et al. A randomized controlled trial of radiofrequency ablation with, ethanol injection for small hepatocellular carcinoma[J]. Gastrocnterology, 2007, 129 (1) : 122-130.
[12]Lin SM,Lin CJ,Lin CC, et al. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less[J]. Gut, 2007, 54 ( 8) :1151-1156.
[13]Mulier S,Mulier P,Ni Y, et al. Comp lications of radiofrequency coagulation of liver turmours [J]. Br J Surg, 2006, 89 (10) :1206-1222.
[14]陈敏山,郑云,张亚奇,等.经皮射射频消融与手术切除治疗小肝癌的疗效比较[J].中华医学杂志,2005,85(2):80-83.
[15]Lu MD Chen JW,XieXY,et.al Hepatocellularcarcinoma , US-guided percutaneous microwave coagulation therapy[J]. Radiology,2006,221(8):167—172.
[16]Richly H, Kup sch P, Passage K, et al. Results of a phase I trial of BAY 43-29006 in combination with doxorubicin in patients with primary hepatic cancer [J]. Int J Clin Pharmacol Ther, 2007, 42(11) : 650-651.
[17]Philip PA,MahoneyMR,Allmer C, et al. PhaseⅡstudy of Erlotinib(OSI-774) in patients with advanced hepatocellular cancer [J]. J Clin Oncol, 2006, 23 (27) : 6657-6663.
[18]张智坚,吴孟超,陈汉,等.术后肝动脉化疗栓塞对提高肝细胞癌术后无瘤生存率的意义[J].中华外科杂志,2002,4O(5):329-331.
[19]Yamakado K,Nakatsuka A.Akeboshi M ,et a1.Combination therapy with radio- frequency ablation and transcatheter chemoembolization for the treatment of hepatocellular carcinoma:Short term recurrences and surviva1.Clin Oncol,2007,11(9):105-109
[20]Lo CM,Hu CL,Chan SC,et a1.A randomized,controled trial ofpostoperative adjuvant interferon therapy after resection of hepatocellular carcinoma[J].Ann Surg,2007,245(6):831—842.